Global Economic Growth and Healthcare Spending: Weakened global economic growth due to conflicts, as indicated by IMF downgrades, could lead to reduced investment in biotech research and development, potentially impacting demand for BioLife Solutions' bioproduction products and services. BioLife Solutions operates in the cell and gene therapy (CGT) industry, which relies on consistent funding for research, clinical trials, and commercialization.

Biotech Investment and Funding Environment: Despite US job growth, overall global economic concerns could make investors more cautious. This may affect venture capital and public market funding for early-stage and high-growth biotech companies, including BioLife Solutions' customer base, which in turn could influence BioLife's revenue streams.

Regulatory Landscape for Cell & Gene Therapies: The cell and gene therapy market, which BioLife Solutions serves, is highly dependent on regulatory approvals for new therapies. Any changes, accelerations, or slowdowns in the approval processes by regulatory bodies like the FDA could significantly impact the commercialization pipeline and the overall growth trajectory of the CGT market, directly affecting BioLife Solutions' business.